NCT04075916View on ClinicalTrials.gov

A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

July 15, 2025

Study Completion Date

January 30, 2026

Conditions
End Stage Renal Disease
Interventions
DRUG

Epclusa

All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.

Trial Locations (11)

10032

New York Presbyterian Hospital/Columbia University, New York

19104

Hospital of the University of Pennsylvania, Philadelphia

21287

Johns Hopkins, Baltimore

29425

Medical University of South Carolina, Charleston

32608

University of Florida, Gainesville

33136

Jackson Memorial Hospital/University of Miami, Miami

35294

University of Alabama at Birmingham, Birmingham

37235

Vanderbilt University, Nashville

44195

Cleveland Clinic, Cleveland

45267

University of Cincinnati, Cincinnati

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Pennsylvania

OTHER